

FILE COPY

PTO FORM 4/92

FORM PTO-1449

**LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION
DISCLOSURE STATEMENT**

ATTY. DOCKET

10872/502

SERIAL NO.

APPLICANT

Robert L. Gendron, Helene
Paradis

FILING DATE

GROUP 1635

Exam
Init.

DOCUMENT NUMBER

DATE

NAME

CLASS

SUB CLASS

DOCUMENT NUMBER

DATE

COUNTRY

CLASS

SUB CLASS

OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

1. Sambrook, J., Fritsch, E. F., and Maniatis, T. *Molecular Cloning, A Laboratory Manual*. 2nd, Cold Spring Harbor Laboratory Press (eds.), New York, 1989.
2. Mullen, J. R., Kayne, P. S., Moerschell, R. P., Tsunasawa, S., Gribskov, M., Colavito Shepanski, M., Grunstein, M., Sherman, F., and Sternglanz, R. Identification and characterization of genes and mutants for an N-terminal acetyltransferase from yeast. *EMBO J.*, 8: 2067-2075, 1989.
3. Ouchida, M., Ohno, T., Fujimura, Y., Rao, V.N., and Reddy, E.S. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. *Oncogene*, 11: 1049-1054, 1995.
4. Kovar, H., Aryee, D. N., Jug, G., Henockl, C., Schemper, M., Delattre, O., Thomas, G., and Gadner, H. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. *Cell Growth Differ.*, 7: 429-437, 1996.
5. Gendron, R. L., Tsai, F. Y., Paradis, H., Arcenci, R. J. Induction of embryonic vasculogenesis by bFGF and LIF in vitro and in vivo. *Dev. Biol.*, 177: 332-346, 1996.
6. Toretzky, J.A., Connell, Y., Neckers, L., Bhat, N.K. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. *J. Neurooncol.*, 31: 9-16, 1997.
7. Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H., and Iwamoto, Y. EWS-Flil antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. *J. Clin. Invest.*, 99: 239-247, 1997.
8. May, W. A., Arvand, A., Thompson, A. D., Braun, B. S., Wright, M., and Denny, C. T. EWS/FLI1-induced manic fringe renders NIH 3T3 cells tumorigenic. *Nat. Genet.*, 17: 495-497, 1997.
9. Good, W.V., Paradis, H., Adams, L.C. and Gendron, R. L. Ocular spatial distribution of tubedown-1 (tbdn-1), a novel acetyltransferase regulated in endothelial cell differentiation. The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting May 9-14, 1998, Fort Lauderdale, Florida.
10. Invited participant in *Electronic Workshop on Genetic Manipulation in Animals: Advanced Transgenesis and Cloning*. National Institute of Standards and Technology, U.S. Department of Commerce, Advanced Technology Program Website: <http://www.atp.nist.gov/atc/atc-6.htm>. September, 1998. Prospects and hurdles in optimizing the vascular support of engineered tissues.
11. Fizazi, K., Dohollou, N., Blay, J. Y., Guerin, S., Le Cesne, A., André, F., Pouillart, P., Tursz, T., and Nguyen, B. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. *J. Clin. Oncol.*, 16: 3736-3743, 1998.
12. Liebermann, D. A., and Hoffman, B. MyD genes in negative growth control. *Oncogene*, 17: 3319-3329, 1998. ✓
13. Gewirtz, A. M., Sokol, D. L., and Ratajczak, M. Z. Nucleic acid therapeutics: state of the art and future prospects. *Blood*, 92: 712-736, 1998.

Karen A. LaComine

07-25-02



26874

PATENT, TRADEMARK OFFICE

PTO FORM 4/92

FORM PTO-1449		ATTY. DOCKET	10872/502	SERIAL NO.	07/836 40
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT	Robert L. Gendron, Helene Paradis		
		FILING DATE		GROUP	168
Exam Init.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS
OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)					

14. Gendron, R. L., Adams, L.C. and Paradis, H. Tubedown-1, a novel acetyltransferase associated with vascular remodeling. *Experimental Biology '99*. Washington, DC, April, 1999.
15. Palumbo, J. S., and Zwerdling, T. Soft tissue sarcomas of infancy. *Semin. Perinatol.*, 23: 299-309, 1999. ✓
16. Arndt, C. A., and Crist, W. M. Common musculoskeletal tumors of childhood and adolescence. *N. Engl. J. Med.*, 341: 342-352, 1999.
17. Amann, G., Zoubek, A., Salzer-Kuntschik, M., Windhager, R., and Kovar, H. Relation of neurological marker expression and EWS gene fusion types in MIC2/CD99-positive tumors of the Ewing family. *Hum. Pathol.*, 30: 1058-1064, 1999.
18. Thompson, A. D., Teitell, M. A., Arvand, A., and Denny, C. T. Divergent Ewing's sarcoma EWS/ETS fusions confer a common tumorigenic phenotype on NIH3T3 cells. *Oncogene*, 18: 5506-5513, 1999.
19. Hahm, K. B., Cho, K., Lee, C., Im, Y. H., Chang, J., Choi, S. G., Sorensen, P. H., Thiele, C. J., and Kim, S. J. Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein. *Nat. Genet.*, 23: 222-227, 1999.
20. Lin, P. P., Brody, R. I., Hamelin, A. C., Bradner, J. E., Healey, J. H., and Ladanyi, M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. *Cancer Res.*, 59: 1428-1432, 1999.
21. Polevoda, B., Norbeck, J., Takakura, H., Blomberg, A., and Sherman, F. Identification and specificities of N-terminal acetyltransferases from *Saccharomyces cerevisiae*. *EMBO J.*, 18: 6155-6168, 1999.
22. Coffman, F. D., and Studzinski, G. P. Differentiation-related mechanisms which suppress DNA replication. *Exp. Cell. Res.*, 248: 58-73, 1999.
23. Im, S. A., Gomez-Manzano, C., Fueyo, J., Liu, T. J., Ke, L. D., Kim, J. S., Lee, H. Y., Steck, P. A., Kyritsis, A. P., and Yung, W. K. Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. *Cancer Res.*, 59: 895-900, 1999.
24. West, D. C. Ewing sarcoma family of tumors. *Curr. Opin. Oncol.*, 12: 323-329, 2000.
25. de Alava, E., and Gerald, W. L. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. *J. Clin. Oncol.*, 18: 204-213, 2000.
26. Im, Y. H., Kim, H. T., Lee, C., Poulin, D., Welford, S., Sorensen, P. H., Denny, C. T., and Kim, S. J. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. *Cancer Res.*, 60: 1536-1540, 2000.

Karen A. Lacourciere

07-25-02

PTO FORM 4/92							
FORM PTO-1449				ATTY. DOCKET	10872/502	SERIAL NO.	07/1831/40
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT				APPLICANT	Robert L. Gendron, Helene Paradis		
				FILING DATE		GROUP 635	
Exam Init.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	
OTHER ART (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)							

- KAL 27. Gendron, R. L., Adams, L. C., and Paradis, H. Tubedown-1, a novel acetyltransferase associated with blood vessel development. Dev. Dyn., 218: 300-315, 2000.
- KAL 28. Bromberg, J., Darnell, J. E. Jr. The role of STATs in transcriptional control and their impact on cellular function. Oncogene, 19: 2468-2673, 2000.
- KAL 29. Yuen, A. R., and Sikic B. I. Clinical studies of antisense therapy in cancer. Front. Biosci., 1: D588-593, 2000. ✓
- KAL 30. Gewirtz, A.M. Oligonucleotide therapeutics: a step forward. J. Clin. Oncol., 18: 1809-1811, 2000.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

CINLibrary/1044648.1

Kam Afacan

07-25-02